Analyst Scott Fidel of Goldman Sachs maintained a Buy rating on Cigna, with a price target of $335.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Scott Fidel has given his Buy rating due to a combination of factors, including confidence in Cigna’s leadership transition and earnings outlook. He views the planned handover from long‑time CEO David Cordani to Brian Evanko as preserving strategic continuity, as Evanko is a seasoned internal executive with deep experience across Cigna’s financial, healthcare, and government segments.
Fidel also highlights that management reaffirmed robust 2026 financial targets, including strong per‑share earnings and solid profit contributions from both Evernorth and Cigna Healthcare, supporting an attractive valuation. His $335 price target is based on applying a 10x P/E multiple to next‑twelve‑month earnings, which he believes adequately compensates for risks such as specialty pharmacy competition, PBM regulation, Part D exposure, and macroeconomic uncertainty.
In another report released yesterday, TipRanks – xAI also reiterated a Buy rating on the stock with a $327.00 price target.
CI’s price has also changed slightly for the past six months – from $300.480 to $283.930, which is a -5.51% drop .